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Gregory L. Moneta, MD, Section EditorEffect of Ramipril on Walking Times and Quality of Life Among
Patients With Peripheral Artery Disease and Intermittent
Claudication. A Randomized Controlled Trial
Ahimastos AA, Walker PJ, Askew C, et al. JAMA 2013;309:453-60.
Conclusion: In patients with intermittent claudication, 24 weeks of
treatment with ramipril improves pain-free and maximum treadmill walking
times compared with placebo and is associated with a signiﬁcant increase in
the physical functioning component of the Short-Form 36 Health Survey
(SF-36; Quality Metrics, Lincoln, RI).
Summary: Drug treatments to improve walking distance in patients
with intermittent claudication generally have limited efﬁcacy. Increased
walking distances of between 12% and 16% can be expected. Of the drugs
approved for treatment of intermittent claudication by the United States
(U.S.) Food and Drug Administration for use in the U.S., pentoxifylline
and cilostazol increase walking distance by 15% and 25%, respectively
(Stevens JW et al, Br J Surg 2012;99:1630-8). A previous pilot study reported
that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, improves
treadmill assessed pain-free and maximum walking time (Ahimastos AA et
al, Ann Intern Med 2006;144:660-4). Other trials of ACE inhibitors in
patients with intermittent claudication have been equivocal. The authors,
therefore, performed this investigator-initiated trial to examine the associa-
tion of ramipril therapy for 24 weeks on walking distance and health-related
quality of life. To make the study as generalizable as possible, patients with
diabetes, aortoiliac, and infrainguinal disease were included. This was
a randomized, double-blind, placebo-controlled trial conducted in 212
patients with peripheral arterial disease. Patients were a mean age of 65.5
years (standard deviation, 6.2 years). The trial was initiated in May 2008
and completed in August of 2011 and was conducted at three hospitals
in Australia. Patients were randomized to receive 10 mg/d ramipril (n ¼
106) or matching placebo (n ¼ 106) for 24 weeks. The main outcome
measures were maximum and pain-free walking times recorded during a stan-
dard treadmill test.Walking ability was assessed with theWalking Impairment
Questionnaire. Quality of life was assessed with the SF-36. Compared with
placebo at 6 months, ramipril was associated with a 70-second (95% conﬁ-
dence interval [CI], 60-89 seconds) increase in mean pain-free walking
time (P < .001). Maximum walking time increased a mean of 255 seconds
(95% CI, 215-195 seconds) compared with placebo in those receiving ram-
ipril (P < .001). Ramipril compared with placebo also improved Walking
Impairment Questionnaire median distance score by 13.8 (95% CI, 12.2-
15.5), speed score by 13.3 (95% CI, 11.9-15.2), and stair climbing score
by 25.2 (95%CI, 25.1-29.4; P< .001 for all comparisons). The SF-36 overall
median physical component summary score improved by 8.2 (95% CI,
3.6-11.4; P ¼ .02) in the ramipril group compared with placebo. Ramipril
did not affect the SF-36 median mental component summary score.
Comment: This is the ﬁrst study with adequate power to demonstrate
treatment with an ACE inhibitor can be associated with improved treadmill
walking performance in patients with intermittent claudication secondary to
atherosclerotic disease. Whereas the mechanism of beneﬁt of ACE inhibitors
in patients with intermittent claudication is unknown, the magnitude of
beneﬁt demonstrated here exceeds that of the U.S. Food and Drug Admin-
istration-approved drugs for treatment of intermittent claudication. Logi-
cally, the next step would be a head-to-head comparison of ramipril and
cilostazol in the medical management of intermittent claudication.Evolving Patterns of Vascular Surgery Care in the United States: A
Report From the American Board of Surgery
Valentine RJ, Rhodes RS, Jones A, et al., the Members of the Vascular
Surgery Board of the American Board of Surgery. J Am Coll Surg
2013;216:886-93.
Conclusion: Most general surgeons do not perform any major
vascular procedures. Younger general surgeons are performing fewer such
procedures than their older counterparts. The opposite is true for vascular
surgeons.
Summary: A 2011 report on general surgery workloads and practice
patterns in theUnited States indicated that a substantial proportion of general
surgical procedures are performed by subspecialists and that general surgeons276were still performing a considerable number of specialty operations, including
vascular surgery operations (Valentine RJ et al, Ann Surg 2011;254:520-6).
However, because endovascular procedures are now accepted options for
some open vascular operations and general surgery residents receive little
training in endovascular techniques and progressively less open operative
vascular experience, it would be reasonable to assume fewer vascular surgery
procedures are performed by practicing general surgeons. This report sought
to detail the effect of changes in vascular surgery on the practice patterns of
general surgeons. The authors sought to evaluate the type of vascular proce-
dures performed by general surgeons and to compare practices of vascular
surgeons vs general surgeons at different points in their careers. The over-
arching goal was to assess over all trends in the pattern of vascular surgical
care. Case logs of surgeons seeking recertiﬁcation in surgery from 2007 to
2009 were reviewed. Data from 3362 physicians certiﬁed only in general
surgery were compared with 363 also certiﬁed in vascular surgery. Indepen-
dent variables were compared using factorial and analysis of variance. General
surgeons performed a mean number of 10 6 51 major vascular procedures,
whereas vascular surgeons performed a mean number of 192 6 209 major
vascular procedures (P < .001). Of the total vascular procedures performed,
31% were performed by general surgeons. Compared with vascular surgery,
general surgeons performed signiﬁcantly fewer vascular procedures in all
major procedure categories. General surgeons recertiﬁed at 10 years per-
formed fewer vascular procedures (6.7 6 47) than those recertifying at 20
years (11.56 48) and 30 years (13.66 59; P< .01). Vascular surgeons certi-
fying at 10 years performedmore vascular procedures (2356 237) compared
with those recertifying at 20 years (1576 173) and 30 years (1046115). The
mean number of vascular procedures performed was not different for sex,
geographic location, or practice type after controlling for other variables.
Comment: The opposing trends in vascular procedures performed by
general surgeons and vascular surgeons indicate vascular procedures are
shifting from general surgery to vascular surgery in modern surgical practice.
This is not particularly surprising. The shift away from general surgeons per-
forming vascular operations is probably even more dramatic than indicated.
Vascular operations performed by cardiothoracic surgeons, osteopathic
surgeons, transplant surgeons, and endovascular procedures performed by
cardiologists and interventional radiologists were not included in the data
analysis. The higher work load of younger vascular surgeons, compared
with older vascular surgeons, suggests there may be limited capacity for
vascular surgery as a specialty to capture more of the overall market for
vascular surgical procedures without increasing the number of trainees.Females With Subclavian Vein Thrombosis May Have an Increased
Risk of Hypercoagulability
Likes K, Rochlin D, Nazarian SM, et al. JAMA Surg 2013;148:44-9.
Conclusion: Young women with spontaneous subclavian/axillary
vein thrombosis should be considered for testing for the presence of a hyper-
coagulable state.
Summary: The prevalence of hypercoagulability in patients with axillo-
subclavian vein thrombosis is debated. Primary axillosubclavian vein throm-
bosis is generally related to a lesion in the subclavian vein that consistently
occurs w1 cm outside the subclavian jugular vein junction. Whether this is
secondary to purely anatomic factors, the combination of an anatomic factors
and activity, or activity alone, is debated. Because not all patients with primary
subclavian axillary vein thrombosis have a history of signiﬁcant activity and
a few may not have the usual underlying anatomic abnormality, a hypercoag-
ulable state may possibly play a role in the development of spontaneous axil-
losubclavian vein thrombosis in some cases. In this study, the authors
reviewed their patients tested for hypercoagulability who presented to their
institution with subclavian/axillary vein thrombosis. This was a retrospective
analysis of a database that contains patients from August 2003 to June 2011.
According to the authors, patients were tested for hypercoagulability if they
presented with axillary/subclavian vein thrombosis not associated with signif-
icant activity. What constituted signiﬁcant activity was not clearly deﬁned. In
addition to hypercoagulability testing, patients were also reviewed for short-
term anatomic ﬁndings and clinical outcomes. During the study interval, 143
patients presented with primary axillary/subclavian vein thrombosis. They
were a mean age of 32 years (range, 16-71 years). Of these patients, 55 (43
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underwent hypercoagulable testing. Some abnormality of coagulation was
discovered in 14 patients (25.5%), comprising 12 women and two men,
with a mean age of 27 years (range 16-46 years). A factor V Leiden mutation
was present in six patients, protein S deﬁciency in four, and a plasminogen-
activator inhibitor-1 deﬁciency in two. One patient each had protein C deﬁ-
ciency and anticardiolipin antibodies, factor V mutation, factor II mutation,
and antiphospholipid antibodies. Patients were initially treated with ﬁrst rib
recession and scalenectomy but not with venous reconstruction. At 2 weeks
postoperatively, patients were assessed by venography for possible venoplasty
of stenotic or occluded veins. In the 14 patients with hypercoagulability, 10
(71%), had stenotic or occluded veins. At 2 weeks, 32 of 41 patients (78%)
tested for hypercoagulability, but with negative ﬁndings, had stenotic or
occluded veins. Of the 82 patients not tested for hypercoagulability at 2
weeks, 53 (61%) had stenotic or occluded veins by duplex scan assessment.
Comment: The authors found some patients with abnormalities of
coagulation in their series. Their suggestion that hypercoagulability testing
be considered in some patients with axillosubclavian vein thrombosis there-
fore seems reasonable. The data here give us some idea of what one will ﬁnd
if one initiates hypercoagulability testing in selected patients with sponta-
neous axillary/subclavian vein thrombosis. The nature of the data and the
limited analysis possible from this sort of data makes this basically a “hypoth-
esis seeking” study. It does not really tell you what to do with that informa-
tion once you ﬁnd it or if the “hypercoagulability” was the primary inciting
problem, a contributing problem, or would not really be much of a problem
at all in the absence of compression of the vein!Statins Reduce Neurologic Injury in Asymptomatic Carotid
Endarterectomy Patients
Heyer EJ, Mergeche JL, Bruce SS, et al. Stroke 2013;44:1150-2.
Conclusion: Preoperative statin use is associated with less neurologic
injury after carotid endarterectomy (CEA) for asymptomatic stenosis.
Summary: There is considerable controversy about the current
therapeutic index of CEA for asymptomatic carotid stenosis. Given what
everyone agrees is a relatively narrow therapeutic index for CEA in the treat-
ment of patients with asymptomatic carotid stenosis, there is considerable
interest in adjunctive measures to potentially improve even further
outcomes of CEA for asymptomatic carotid stenosis. The Asymptomatic
Carotid Surgery Trial suggested a reduction in perioperative risk of stroke
and death from 6% to 2% for those on “lipid-lowering agents” (Halliday
A et al, Lancet 2010;376:1074-84). However, data on 1252 patients under-
going CEA for asymptomatic stenosis in Canada failed to demonstrate
a protective effect of statins (Kennedy J et al, Stroke 2005;36:2072-6). In
addition to stroke, effects of CEA and other carotid interventions on post-
operative cognitive dysfunction are also of interest. Potential effects of statins
on postoperative cognitive dysfunction have not been studied previously. In
this study, the authors sought to determine whether statins were neuropro-
tective in a cohort of asymptomatic CEA patients taking statin medications.
This study deﬁned neurologic injury after CEA as both clinical stroke and
signiﬁcant cognitive dysfunction. Agreeing to participate in the study were
328 asymptomatic patients with carotid stenosis scheduled for elective
CEA. Patients were evaluated for perioperative stroke and cognitive dysfunc-
tion. Cognitive dysfunction was determined by a battery of neuropsychomet-
ric tests performed preoperatively and 1 day postoperatively (Heyer EJ et al,
ArchNeurol 2002;59:217-22). Patients taking a statinmedication at the time
of their CEA had a lower incidence of clinical stroke (0.0% vs 3.1%; P ¼ .02)
and a lower incidence of cognitive dysfunction (11% vs 20.0%; P ¼ .03).
Application of a multiple variant regression model indicated statin use was
signiﬁcantly associated with decreased odds of cognitive dysfunction (odds
ratio, 0.51; 95% conﬁdence interval, 0.27-0.96; P ¼ .04).
Comment: Previous studies have suggested that postoperative cogni-
tive dysfunction can predict disability and perhaps even early death (Stein-
metz J et al, Anesthesiology 2009;110:548-55). Therefore, although this
was a single-center study and such things as reasons for statin medication
and duration of statin medication, as well as dosages of statin medications,
were not controlled, the data are intriguing enough that more formal eval-
uation on the effects of statin medications in preserving cognitive function
in CEA patients, while controlling for the obvious variables of dosage, dura-
tion and type of statin medication, would seem worthwhile.Nationwide Outcomes of Surgical Embolectomy for Acute Pulmonary
Embolism
Kilic A, Shah AS, Conte JV, et al. J Thorac Cardiovasc Surg 2013;145:373-7.
Conclusion: There is a nationwide inpatient mortality rate of 27.2%
after pulmonary embolectomy. Death after pulmonary embolectomy is
affected by factors other than arena of care.Summary: Acute pulmonary embolism (PE) causesw300,000 deaths
each year in the United Sates (Heit JA et al, US Blood 2005;106:267a).
Surgical pulmonary embolectomy is an option for patients with severe PE
and contraindications to thrombolysis or who have persistent hypotension
after initial therapy. Previous outcomes reported for surgical pulmonary
embolectomy have generally been limited to small patient cohorts. In the
present study, the authors evaluated nationwide outcomes of surgical embo-
lectomy for acute PE. The authors studied adult patients undergoing
surgical embolectomy for acute PE from 1999 to 2008. Patients were iden-
tiﬁed in the weighted Nationwide Inpatient Sample. The primary end point
was in-patient mortality. Multivariate logistic regression analysis was con-
ducted to identify independent predictors for patient mortality. During
the study period, 2709 eligible patients were identiﬁed as undergoing
surgical embolectomy for acute PE. Mean age was 57.0 6 16.0 years,
and 1242 (48.8%) were women. Before surgical embolectomy, 10.3% of
the patients had undergone thrombolysis. Overall inpatient mortality was
27.2%. By multivariate analysis, increased Charlson Comorbidity Index
(odds ratio, 1.37; 95% conﬁdence interval, 1.12-1.69; P ¼ .003) increased
the odds of inpatient death. Black patients were more than twofold more
likely to die during hospitalization than white patients (odds ratio, 2.29;
95% conﬁdence interval, 1.18-4.46; P ¼ .02). Univariate analysis found
age, payment type, hospital location (urban vs rural), hospital embolectomy
volume, and surgical embolectomy volume were associated with in-patient
mortality (each P < .2). None of these factors, however, correlated with
mortality in the multivariate model.
Comment: Many variables that one would expect to be associated with
increased mortality for an operation with high mortality were, in fact, found
not to inﬂuence the mortality of surgical embolectomy for acute PE. This
likely relates to the fact that no surgeon or hospital has a large volume of expe-
rience with this particular procedure. There were in fact only 2.3 cases per-
formed each year in hospitals that performed the procedure. This is likely
too few cases for pathways of care, surgical expertise, and anesthesia
expertise to generate an effect. The authors suggest that it may be for prudent
for centers with qualiﬁed surgeons to avoid delays in treatment rather than
transfer care because of a perception of improved outcomes. However, the
oppositemay also be true, in that development of a regional center for surgical
pulmonary embolectomy may allow acquisition of sufﬁcient number of cases
in a single center to actually improve outcomes of this procedure.Surgical Never Events in the United States
Mehtsun WT, Ibrahim AM, Diener-West M, et al. Surgery 2013;153:465-
72.
Conclusion: Patient and provider characteristics may help guide
prevention strategies for surgical “never events.”
Summary: Surgical “never events” include retained foreign body,
wrong site surgery, wrong patient surgery, and wrong procedure operations.
Despite agreement that these are always avoidable, they persist within real-
world surgical practice. “Never events” clearly can be catastrophic for a patient
but also destructive to a surgeon’s career and a hospital’s reputation. They
may be a surrogate marker for unsafe hospital systems and a poor safety
culture (Reason J, Qual Health Care 1995;4:80-90). This study addressed
surgical “never events” with respect to the ﬁnancial burdens they may place
on the health care system (malpractice claim payment) and characteristics
of providers involved with occurrence of surgical “never events.”The authors
used the National Practitioner Databank, a federal repository of medical
malpractice claims, to identify malpractice settlements and judgments of
surgical “never events.” Patient outcomes, payment amounts, and provider
characteristics were evaluated. The authors were able to identify 9744 paid
malpractice settlements and judgments for surgical “never events.” This
was for the period of 1990 to 2010. Malpractice payments for surgical “never
events” totaled $1.3 billion. Death occurred in 6.6% of patients, permanent
injury in 32.9%, and temporary injury in 59.2%. The authors estimate, based
on literature rates of surgical adverse events resulting in paid malpractice
claims, that 4082 surgical “never events” occur each year in theUnited States.
With respect to malpractice payments, increased malpractice claim payments
were associated with severe patient outcomes and claims involving a physician
with multiple malpractice reports. Of physicians named in a surgical “never
event” claim, 12.4% were later named in at least one future surgical “never
event” claim.
Comment: It has been suggested that medical errors occur when
there is a faulty system in a context of a weak culture for safety at an insti-
tutional level (Gosbee J, Qual Saf Health Care 2002;11:352-4). The
problem may be greater than alluded to in this study, because only 4% of
serious preventable adverse events result in complaints (Bismark MM et
al, Qual Saf Health Care 2006;15:17-22). It is the responsibility of hospitals
to support a culture of safety and the responsibility of physicians to support
this culture for the beneﬁt of their patients.
